Evidence map›Paper›PMID 27028725›Full record

ArticleXenotransplantation2016

Susceptibility of porcine endogenous retrovirus to anti-retroviral inhibitors.

Takele Argaw, Winston Colon-Moran, Carolyn Wilson

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Xenotransplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 34 citations in OpenAlex.

  1. Monitoring for PERV Following Xenotransplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2024
    Review
  2. Review
  3. Article
  4. Review
  5. Genetically engineered pigs for xenotransplantation: Hopes and challenges.Frontiers in cell and developmental biology · 2022
    Review
  6. Review
  7. Review
  8. Article
  9. Infection in xenotransplantation: opportunities and challenges.Current opinion in organ transplantation · 2019
    Review
  10. Regulatory barriers to xenotransplantation.Current opinion in organ transplantation · 2019
    Review
  11. Solid organ transplantation in the 21Annals of translational medicine · 2018
    Review
  12. Review
  13. Xenotransplantation: past, present, and future.Current opinion in organ transplantation · 2017
    Review
  14. Review
  15. Review
  16. New Phase of Growth for Xenogeneic-Based Bioartificial Organs.International journal of molecular sciences · 2016
    Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Takele ArgawGene Transfer and Immunogenicity Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.
Winston Colon-MoranGene Transfer and Immunogenicity Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.
Carolyn WilsonGene Transfer and Immunogenicity Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.
Center for Biologics Evaluation and Research · USUnited States Food and Drug Administration · US

Funding

Intramural FDA HHS FD999999
6 · The paper itself

Abstract

backgroundPorcine endogenous retrovirus (PERV) is an endogenous retrovirus that poses a risk of iatrogenic transmission in the context of pig-to-human xenotransplantation. The lack of a means to control PERV infection in the context of pig-to-human xenotransplantation is a major concern in the field. In this study, we set out to evaluate the ability of currently licensed anti-HIV drugs, and other types of anti-retroviral compounds, to inhibit PERV infection in vitro.

methodsWe used target cells stably expressing one of the known PERV viral receptors, an infectious molecular clone, PERV-A 14/220, and at least one drug from each class of anti-retroviral inhibitors as well as off-label drugs shown to have anti-viral activities. The susceptibility of PERV-A 14/220 LacZ to the anti-retroviral drugs was determined from infected cells by histochemical staining.

resultsWe extend the results of previous studies by showing that, in addition to raltegravir, dolutegravir is found to have a potent inhibitory activity against PERV replication (IC50 8.634 ±0.336 and IC50 3.06 ± 0.844 nM, respectively). The anti-HIV drug zidovudine (AZT) showed considerable anti-PERV activity with IC50 of 1.923 ±0.691 μM as well.

conclusionsThe study results indicate that some of the licensed anti-retroviral drugs may be useful for controlling PERV infection. However, the efficacy at nanomolar concentrations put forward integrase inhibitors as a drug that has the potential to be useful in the event that xenotransplantation recipients have evidence of PERV transmission and replication.

Indexed as

AnimalsAnti-Retroviral AgentsCell LineCells, CulturedEndogenous RetrovirusesRabbitsSwineTransplantation, HeterologousVirus DiseasesAnti-Retroviral Agentsanti-retroviralporcine endogenous retrovirusxenotransplantation

Identifiers

PMID27028725
PMCPMC4873160
OpenAlexW2320919073

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.